Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/174374
A pediatric regimen for adolescents and young adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Background: Pediatric-based or -inspired trials have improved the prognosis of adolescents and young adults (AYA) with Philadelphia chromosome-negative (Ph-neg) acute lymphoblastic leukemia (ALL). Methods: This study reports the results of treatment of the ALLRE08 trial, a full pediatric trial for AYA aged 15-30 years with standard-risk (SR) ALL. Results: From 2008 to 2018, 89 patients (38 adolescents [15-18 years] and 51 young adults [YA, 19-30 years], median age: 20 [15-29] years) were enrolled in the ALLRE08 trial. The complete response (CR) was 95%. Twenty-two patients were transferred to a high-risk (HR) protocol because of poor marrow response on day 14 (n = 20) or high-level of end-induction minimal residual response (MRD ≥ 0.25%, n = 2). Cumulative incidence of relapse (CIR) at 5 years was 35% (95%CI: 23%-47%), with significant differences between adolescents and YA: 13% (4%-28%) vs 52% (34%-67%), P = .012. No treatment-related mortality was observed in 66/66 patients following the ALLRE08 trial vs 3/23 patients moved to a HR trial. The estimated 5-year overall survival (OS) was 74% (95%CI: 63%-85%), with significantly higher rates for adolescents vs YA: 87% (95%CI: 74%-100%) vs 63% (46%-80%), P = .021. Although CIR or OS were lower in patients who were transferred to a HR trial, the differences were not statistically significant (CIR: 34% [21%-47%] vs 37% [14%-61%]; OS: 78% [66%-90%] vs 61% [31%;91%]). Conclusion: A full pediatric trial is feasible and effective for AYA with Ph-neg, SR-ALL, with better results for adolescents than for YA. Outcome of patients with poor early response rescued with a HR trial was not significantly inferior.
Matèries
Matèries (anglès)
Citació
Citació
RIBERA, Josep maria, MORGADES, Mireia, MONTESINOS, Pau, TORMO, Mar, MARTÍNEZ CARBALLEIRA, Daniel, GONZÁLEZ CAMPOS, José, GIL, Cristina, BARBA, Pere, GARCÍA BOYERO, Raimundo, COLL, Rosa, PEDREÑO, María, RIBERA, Jordi, MERCADAL, Santiago, VIVES, Susana, NOVO, Andrés, GENESCÀ, Eulàlia, HERNÁNDEZ RIVAS, Jesús maría, BERGUA, Juan, AMIGO, María luz, VALL LLOVERA, Ferran, MARTÍNEZ SÁNCHEZ, Pilar, CALBACHO, María, GARCÍA CADENAS, Irene, GARCIA GUIÑON, Antonio, SÁNCHEZ SÁNCHEZ, María josé, CERVERA, Marta, FELIU, Evarist, ORFAO, Alberto, PETHEMA Group. A pediatric regimen for adolescents and young adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. _Cancer Medicine_. 2020. Vol. 9, núm. 7, pàgs. 2317-2329. [consulta: 15 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/174374]